Can I Take Ashwagandha with CJC-1295?

What Is CJC-1295 Modified GRF and How Does It Work?

CJC-1295 modified GRF (also sold as Mod GRF 1-29 or CJC-1295 without DAC) is a synthetic 29-amino-acid analogue of endogenous growth hormone-releasing hormone (GHRH). It binds GHRH receptors on pituitary somatotrophs, amplifying the natural pulsatile release of growth hormone rather than replacing it entirely. Because of that mechanism, it is frequently combined with a GHRP such as ipamorelin to capitalize on synergistic pituitary stimulation.

CJC-1295 is not FDA-approved as a finished drug product. It is dispensed by 503A compounding pharmacies under prescriber order and is used in clinical practice for body composition optimization, recovery, and age-related GH decline [1].

Half-Life and Dosing Context

The modified GRF version without the drug affinity complex (DAC) has a half-life of roughly 30 minutes [2]. Standard compounded dosing ranges from 100 mcg to 300 mcg subcutaneously, administered once nightly to coincide with the endogenous GH surge during slow-wave sleep. Five-days-on, two-days-off cycling is common in telehealth protocols to preserve pituitary receptor sensitivity.

The IGF-1 Signal

Downstream of each GH pulse, the liver produces insulin-like growth factor-1 (IGF-1), which is the primary measurable biomarker for CJC-1295 activity. A 2006 study by Teichman et al. (N=65) found that CJC-1295 with DAC raised mean IGF-1 levels by 28 to 43% above baseline over a two-week period, with effects persisting for up to 28 days after a single injection series [3]. Mod GRF 1-29 (without DAC) produces shorter-acting but analogous IGF-1 responses.

What Does Ashwagandha Do Physiologically?

Ashwagandha (Withania somnifera) is an adaptogenic herb whose active constituents include withanolides, withanosides, and alkaloids. Its clinical effects are mediated largely through the hypothalamic-pituitary-adrenal (HPA) axis and, to a lesser degree, the hypothalamic-pituitary-gonadal (HPG) axis.

Cortisol Reduction

The most replicated finding in ashwagandha research is a reduction in serum cortisol. A double-blind RCT by Chandrasekhar et al. (N=64) demonstrated a 27.9% reduction in serum cortisol after 60 days of 300 mg twice-daily KSM-66 extract versus placebo (P<0.001) [4]. A separate 8-week trial by Pratte et al. (N=98) using 500 mg/day of root extract showed a 14.5% cortisol reduction alongside significant improvements in perceived stress scores [5].

Testosterone and LH Effects

Ashwagandha modestly raises luteinizing hormone (LH) and testosterone in men with relative hypogonadism. A 16-week RCT by Wankhede et al. (N=57) found a 15% increase in testosterone and a 17% increase in LH in the ashwagandha group versus placebo [6]. A meta-analysis by Durg et al. (2018) pooling five trials confirmed statistically significant testosterone elevation (weighted mean difference approximately 109 ng/dL) [7].

Thyroid Hormone Elevation

Ashwagandha raises both T3 and T4. A randomized trial by Sharma et al. (N=50) reported significant increases in serum T3 and T4 after eight weeks of 600 mg/day root extract compared to placebo (P<0.05) [8]. This is relevant for anyone on thyroid replacement therapy, as the combination could push thyroid hormone levels above the desired range.

Is the CJC-1295 and Ashwagandha Interaction Pharmacokinetic or Pharmacodynamic?

The interaction is pharmacodynamic, not pharmacokinetic. CJC-1295 is a synthetic peptide administered subcutaneously and cleared renally as amino acid fragments. Ashwagandha withanolides are orally bioavailable small molecules metabolized hepatically via CYP3A4 and CYP2C9 pathways [9]. Because these two agents use entirely different routes of absorption, distribution, metabolism, and excretion, they do not compete for plasma protein binding or alter each other's serum concentrations.

The meaningful question is whether they push the same physiological levers in ways that produce excessive or unexpected effects when combined.

Where Do the Two Agents Overlap Physiologically?

The GH-Cortisol Relationship

Cortisol and GH are broadly antagonistic in their effects on body composition. Elevated cortisol suppresses GH secretion at the level of the hypothalamus by stimulating somatostatin release [10]. Ashwagandha's ability to reduce cortisol by roughly 15 to 28% could therefore reduce somatostatin tone, creating a more permissive environment for CJC-1295-stimulated GH pulses. This is likely an additive benefit rather than a risk, but it means the combination may produce stronger IGF-1 responses than either agent alone.

Testosterone Overlap

Both agents can raise testosterone modestly. CJC-1295 does so indirectly: GH increases IGF-1, which has been shown to stimulate Leydig cell testosterone synthesis [11]. Ashwagandha raises testosterone more directly via LH-mediated signaling [6]. Combining them could push testosterone above the upper reference range in men who are already near the ceiling, which is worth monitoring with periodic lab draws.

HPA Axis Crosstalk

The HPA axis and the GH axis communicate bidirectionally. GHRH itself can attenuate cortisol release in some models by reducing CRH output [12]. Adding an HPA-suppressing adaptogen on top of a GHRH agonist therefore acts on both ends of this feedback loop simultaneously. For most patients this produces a favorable stress-resilience effect, but in individuals with adrenal insufficiency or already-low morning cortisol the combination could produce symptomatic hypocortisolism (fatigue, orthostatic symptoms, salt craving).

Does Ashwagandha Affect the Thyroid Axis Differently When CJC-1295 Is Present?

GH itself has bidirectional effects on thyroid hormones. Supraphysiologic GH raises T3 by increasing peripheral conversion of T4 to T3 via type 1 deiodinase [13]. Ashwagandha independently raises both T3 and T4 [8]. If CJC-1295 is driving IGF-1 and GH toward the upper end of normal, and ashwagandha is simultaneously raising thyroid hormone output, someone on levothyroxine could develop subclinical hyperthyroidism.

Free T3, free T4, and TSH should be checked at baseline and at 8 to 12 weeks after starting either agent, or sooner if symptoms such as palpitations, insomnia, or unintended weight loss appear.

What Does the Evidence Actually Say? (Quality Assessment)

No published RCT has studied CJC-1295 and ashwagandha in combination. The interaction analysis above is built from mechanistic inference, not direct trial data. That is an honest limitation.

What the evidence does support:

• CJC-1295 with DAC raised IGF-1 by 28 to 43% in a Phase 2 trial [3].
• Ashwagandha KSM-66 at 300 mg twice daily reduced cortisol by 27.9% in 60 days [4].
• Ashwagandha raised testosterone by roughly 15% over 16 weeks in a controlled trial [6].
• Ashwagandha significantly altered T3 and T4 in an 8-week RCT [8].

Each of these individual effects is well-documented. The combined pharmacodynamic outcome remains unstudied. Evidence quality for the specific combination should be graded as low by GRADE standards, meaning the estimates of effect could change materially if a direct trial were ever conducted.

HealthRX Interaction Risk Framework for CJC-1295 + Ashwagandha:

| Domain | Individual Effect | Combined Risk Level | |---|---|---| | Cortisol reduction | Additive via separate mechanisms | Low (likely beneficial) | | GH / IGF-1 amplification | Possibly additive | Low-Moderate (monitor IGF-1) | | Testosterone elevation | Additive via separate axes | Low-Moderate (monitor TT) | | Thyroid hormone rise | Additive (T3, T4) | Moderate (monitor fT3, fT4) | | Adrenal suppression | Theoretical only | Low (screen for low baseline cortisol) | | Drug-drug (PK) | None identified | Negligible |

Who Should Be More Cautious?

People on Thyroid Replacement Therapy

Anyone taking levothyroxine (Synthroid, Tirosint) or liothyronine should check thyroid function tests before starting this combination and again at 8 weeks. The Endocrine Society clinical practice guideline for thyroid hormone replacement specifies a target TSH between 0.5 and 2.5 mIU/L for most patients [14]. If TSH drops below that range, the levothyroxine dose may need downward adjustment.

People with Pre-Existing Low Cortisol

A morning cortisol below 10 mcg/dL before starting either agent warrants evaluation for adrenal insufficiency before adding an HPA-modulating adaptogen [15]. The combination is not appropriate without adrenal workup in that context.

People Already on TRT

Men using testosterone replacement therapy alongside CJC-1295 should be aware that adding ashwagandha introduces a third testosterone-raising signal. Total testosterone and free testosterone should be checked before adding ashwagandha to an existing TRT plus peptide protocol.

Women

Most ashwagandha testosterone data comes from male cohorts. Women using CJC-1295 for body composition or recovery goals should be aware that ashwagandha may modestly raise androgens, which can worsen androgenic symptoms (acne, hair thinning) in those with PCOS or baseline hyperandrogenism [16].

Practical Dosing and Timing Guidance

Separating the Doses in Time

Because the interaction is pharmacodynamic rather than pharmacokinetic, time separation does not eliminate the interaction, but it avoids any hypothetical concern about simultaneous peak plasma concentrations affecting pituitary receptor sensitivity. A pragmatic schedule:

• Ashwagandha: 300 to 600 mg of a standardized extract (KSM-66 or Sensoril) taken with dinner, roughly 7 to 9 PM.
• CJC-1295 injection: Subcutaneous injection at bedtime, 10 to 11 PM, after a 2 to 3 hour fast, to maximize the coincidence with slow-wave-sleep GH surge.

This creates a 1 to 2 hour separation and aligns ashwagandha's documented sleep-quality improvement [17] with the pre-sleep period while keeping the injection in the optimal GH-pulse window.

Recommended Starting Doses

• CJC-1295 modified GRF (without DAC): 100 to 200 mcg subcutaneously nightly.
• Ashwagandha KSM-66: 300 mg twice daily or 600 mg once nightly.

Do not start both agents simultaneously on day one. Add ashwagandha to an existing, stable CJC-1295 protocol after at least 4 weeks on the peptide alone. This allows any peptide-related IGF-1 or thyroid changes to stabilize before introducing a second variable.

Monitoring Protocol

A reasonable lab panel before starting this combination and at 8 to 12 weeks:

• IGF-1 (serum): Target mid-to-upper age-adjusted reference range for CJC-1295 optimization.
• Morning cortisol (8 AM serum): Rule out adrenal insufficiency at baseline; recheck if fatigue worsens.
• Free T3, free T4, TSH: Baseline thyroid status; repeat at 8 to 12 weeks.
• Total testosterone and free testosterone: Baseline for men; recheck at 12 weeks if adding ashwagandha.
• DHEA-S (optional): Useful if adrenal axis assessment is needed.
• Fasting insulin and fasting glucose: GH raises insulin resistance modestly; worthwhile in patients with pre-diabetes or metabolic syndrome [18].

The FDA has not established a Recommended Daily Intake for ashwagandha, and CJC-1295 carries no FDA-approved labeling. Monitoring is therefore driven entirely by clinical judgment and the physiological overlap described above, not by package-insert instructions.

What to Do If You Are Already Taking Both

If you are currently taking both without prior lab work, the practical steps are:

1. Order the lab panel listed above now, not at the next scheduled visit.
2. Review thyroid results first, especially if you notice palpitations, heat intolerance, or disrupted sleep. Those are the earliest signs of thyroid over-stimulation.
3. Check morning cortisol if you are experiencing unusual fatigue, especially orthostatic dizziness on waking.
4. Share both your peptide prescription and your supplement list with your prescribing clinician. Many patients underreport supplements because they assume natural products are irrelevant to peptide protocols.

No emergency discontinuation is needed based on current evidence. The risk profile is low to moderate, not high, for the vast majority of otherwise healthy adults.

Summary of the Interaction in Plain Terms

CJC-1295 signals the pituitary to release more GH. Ashwagandha reduces cortisol, modestly raises testosterone, and raises thyroid hormones. These are separate mechanisms operating on related but distinct axes. The two agents may reinforce each other's benefits on body composition and stress resilience, but they also stack their effects on testosterone and thyroid hormones, which requires monitoring. No dangerous drug-drug interaction exists at the pharmacokinetic level.